Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor

Bibliography

• Haller F, et al. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors (GISTs) reveals hypomethylation of SPP1 as an independent prognostic factor. Int J Cancer 2014;136(5):1013-23
   PubMed Web of Science ®Google Scholar
• Crosby JA, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8(1):50-9
   PubMed Web of Science ®Google Scholar
• Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7(6):507-19
   PubMed Web of Science ®Google Scholar
• Yamashita Y, et al. Contrast-enhanced endoscopic ultrasonography can predict a higher malignant potential of gastrointestinal stromal tumors by visualizing large newly formed vessels. J Clin Ultrasound 2014;43(2):89-97
   PubMed Web of Science ®Google Scholar
• Kukar M, et al. Gastrointestinal stromal tumors (GISTs) at uncommon locations: A large population based analysis. J Surg Oncol 2015;111(6):696-701
   PubMed Web of Science ®Google Scholar
• Scherubl H, et al. Management of early asymptomatic gastrointestinal stromal tumors of the stomach. World J Gastrointest Endosc 2014;6(7):266-71
   PubMedGoogle Scholar
• Boikos SA, Stratakis CA. The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine 2014;47(2):401-8
   PubMed Web of Science ®Google Scholar
• Nagata K, et al. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis. J Proteomics 2015;115:132-42
   PubMed Web of Science ®Google Scholar
• Agaram NP, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008;14(10):3204-15
   PubMed Web of Science ®Google Scholar
• Janeway KA, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007;67(19):9084-8
   PubMed Web of Science ®Google Scholar
• Rink L, Godwin AK. Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population. Curr Oncol Rep 2009;11(4):314-21
   PubMedGoogle Scholar
• Prakash S, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 2005;27(4):179-87
   PubMed Web of Science ®Google Scholar
• Carney JA, et al. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977;296(26):1517-18
   PubMed Web of Science ®Google Scholar
• Zhang L, et al. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 2010;34(1):53-64
   PubMed Web of Science ®Google Scholar
• Tarn C, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008;105(24):8387-92
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer 2009;125(12):2991-4
   PubMed Web of Science ®Google Scholar
• Belinsky MG, et al. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle 2008;7(19):2949-55
   PubMed Web of Science ®Google Scholar
• Belinsky MG, et al. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 2013;52(2):214-24
   PubMed Web of Science ®Google Scholar
• Janeway KA, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108(1):314-18
   PubMed Web of Science ®Google Scholar
• Miettinen M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35(11):1712-21
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 2011;103(12):983-7
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, et al. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. Am J Surg Pathol 2011;35(11):1750-2
   PubMed Web of Science ®Google Scholar
• Nannini M, et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 2014;14:685
   PubMed Web of Science ®Google Scholar
• Killian JK, et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 2014;6(268):268ra177
   PubMed Web of Science ®Google Scholar
• Agaimy A, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009;62(7):613-16
   PubMed Web of Science ®Google Scholar
• Agaram NP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008;47(10):853-9
   PubMed Web of Science ®Google Scholar
• Belinsky MG, et al. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer 2009;48(10):886-96
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, et al. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med 2015;4(1):101-3
   PubMed Web of Science ®Google Scholar
• Demetri GD, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295-302
   PubMed Web of Science ®Google Scholar
• Tetzlaff ED, Davey MP. Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor. J Adv Pract Oncol 2013;4(4):238-50
   PubMedGoogle Scholar
• Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol 2011;104(8):888-95
   PubMed Web of Science ®Google Scholar
• Patel BB, et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008;5(3-4):137-49
   PubMedGoogle Scholar
• Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract 2014;2014:357027
   PubMedGoogle Scholar
• Blanke CD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26(4):626-32
   PubMed Web of Science ®Google Scholar
• Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007;38(5):679-87
   PubMed Web of Science ®Google Scholar
• Demetri GD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009;27(19):3141-7
   PubMed Web of Science ®Google Scholar
• Tarn C, et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006;66(10):5477-86
   PubMed Web of Science ®Google Scholar
• Frolov A, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003;2(8):699-709
   PubMed Web of Science ®Google Scholar
• Rink L, et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 2009;8(8):2172-82
   PubMed Web of Science ®Google Scholar
• Tarn C, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005;11(10):3668-77
   PubMed Web of Science ®Google Scholar
• Antonescu CR, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11(11):4182-90
   PubMed Web of Science ®Google Scholar
• Rink L, et al. ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS ONE 2013;8(1):e54477
   PubMedGoogle Scholar
• Ochs MF, et al. Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res 2009;69(23):9125-32
   PubMed Web of Science ®Google Scholar
• Corbin KS, Kindler HL, Liauw SL. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther 2014;7:713-18
   PubMed Web of Science ®Google Scholar
• Joensuu H, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307(12):1265-72
   PubMed Web of Science ®Google Scholar
• Demetri GD, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009;15(18):5902-9
   PubMed Web of Science ®Google Scholar
• Reichardt P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 2015;121(9):1405-13
   PubMed Web of Science ®Google Scholar
• Komatsu Y, et al. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wu L, et al. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Drug Des Devel Ther 2014;8:2061-7
   PubMed Web of Science ®Google Scholar
• Andre C, et al. Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass III. Oncogene 1992;7(4):685-91
   PubMed Web of Science ®Google Scholar
• Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J 1992;11(12):4251-9
   PubMed Web of Science ®Google Scholar
• Shim AH, et al. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci U S A 2010;107(25):11307-12
   PubMed Web of Science ®Google Scholar
• Grassot J, et al. Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains. Mol Biol Evol 2006;23(6):1232-41
   PubMed Web of Science ®Google Scholar
• Spritz RA, et al. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 1994;22(2):431-6
   PubMed Web of Science ®Google Scholar
• Qiu FH, et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988;7(4):1003-11
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Oda Y. Gastrointestinal stromal tumor: Recent advances in pathology and genetics. Pathol Int 2014;65(1):9-18
   PubMed Web of Science ®Google Scholar
• Prenen H, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006;77(1):11-16
   PubMed Web of Science ®Google Scholar
• Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. PLoS ONE 2014;9(9):e107613
   PubMedGoogle Scholar
• Demetri GD, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009;15(18):5910-16
   PubMed Web of Science ®Google Scholar
• Sawaki A, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117(20):4633-41
   PubMed Web of Science ®Google Scholar
• Mita M, et al. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol 2014;74(1):195-204
   PubMed Web of Science ®Google Scholar
• Mahadevan D, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26(27):3909-19
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Choy G, Joshi R, et al. MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRa) and DNA repair protein Rad 51—final results from a first-in-man single agent study. AACR proceedings Abstract 2749 2010;70(8 Suppl):2749
   Google Scholar
• Choy G, et al. Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. Cancer Chemother Pharmacol 2012;70(1):183-90
   PubMed Web of Science ®Google Scholar
• Tibes R, et al. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71(2):463-71
   PubMed Web of Science ®Google Scholar
• Kim EJ,Zalupski MM. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol 2011;104(8):901-6
   PubMed Web of Science ®Google Scholar
• Lassau N, et al. Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs 2012;30(2):765-71
   PubMed Web of Science ®Google Scholar
• Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 2014;6(3):115-27
   PubMed Web of Science ®Google Scholar
• Soria JC, et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 2009;45(13):2333-41
   PubMed Web of Science ®Google Scholar
• Le Cesne A, et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010;46(8):1344-51
   PubMed Web of Science ®Google Scholar
• Adenis A, et al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol 2014;25(9):1762-9
   PubMed Web of Science ®Google Scholar
• Lierman E, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012;26(7):1693-5
   PubMed Web of Science ®Google Scholar
• Zhang J, et al. The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells. Onco Targets Ther 2014;7:2013-19
   PubMed Web of Science ®Google Scholar
• Gozgit JM, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011;10(6):1028-35
   PubMed Web of Science ®Google Scholar
• Garner AP, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 2014;20(22):5745-55
   PubMed Web of Science ®Google Scholar
• Heinrich MC, et al. A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report. in ASCO Annual Meeting. 2014
   Google Scholar
• Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Huynh H, et al. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther 2009;8(1):152-9
   PubMed Web of Science ®Google Scholar
• Guo T, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13(16):4874-81
   PubMed Web of Science ®Google Scholar
• Strumberg D, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
   PubMed Web of Science ®Google Scholar
• Montemurro M, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013;49(5):1027-31
   PubMed Web of Science ®Google Scholar
• Park SH, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30(6):2377-83
   PubMed Web of Science ®Google Scholar
• Versleijen-Jonkers YM, et al. Anti-angiogenic therapy, a new player in the field of sarcoma treatment. Crit Rev Oncol Hematol 2014;91(2):172-85
   PubMed Web of Science ®Google Scholar
• Dey N, De P, Leyland-Jones B. Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours. Br J Cancer 2014
   Google Scholar
• Takahashi R, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003;64(3):266-74
   PubMed Web of Science ®Google Scholar
• Heckman CA, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008;68(12):4754-62
   PubMed Web of Science ®Google Scholar
• Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
   PubMed Web of Science ®Google Scholar
• Drevs J, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25(21):3045-54
   PubMed Web of Science ®Google Scholar
• Judson I, et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res 2014;20(13):3603-12
   PubMed Web of Science ®Google Scholar
• Zhang Y, et al. Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor. World J Gastroenterol 2010;16(37):4716-24
   PubMed Web of Science ®Google Scholar
• El-Rifai W, et al. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000;60(14):3899-903
   PubMed Web of Science ®Google Scholar
• Malumbres M, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118(4):493-504
   PubMed Web of Science ®Google Scholar
• Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3(11):1427-38
   PubMed Web of Science ®Google Scholar
• Li C, et al. PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis. Oncol Lett 2014;7(5):1673-8
   PubMed Web of Science ®Google Scholar
• Schwartz GK, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104(12):1862-8
   PubMed Web of Science ®Google Scholar
• Flaherty KT, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18(2):568-76
   PubMed Web of Science ®Google Scholar
• Paplomata E, O’Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014;6(4):154-66
   PubMed Web of Science ®Google Scholar
• Rossi F, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A 2006;103(34):12843-8
   PubMed Web of Science ®Google Scholar
• Van Looy T, et al. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumours: rationale and efficacy. Clin Cancer Res 2014;20(23):6071-82
   PubMed Web of Science ®Google Scholar
• Floris G, et al. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res 2013;19(3):620-30
   PubMed Web of Science ®Google Scholar
• Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27(41):5527-41
   PubMed Web of Science ®Google Scholar
• Blancafort P, Jin J, Frye S. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol Pharmacol 2013;83(3):563-76
   PubMed Web of Science ®Google Scholar
• Mund C, Lyko F. Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays 2010;32(11):949-57
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1(1):19-25
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150(1):12-27
   PubMed Web of Science ®Google Scholar
• Sharma S, et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol 2014;75(1):87-95
   PubMed Web of Science ®Google Scholar
• Anne M, et al. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther 2013;6:1613-24
   PubMed Web of Science ®Google Scholar
• Floris G, et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009;15(12):4066-76
   PubMed Web of Science ®Google Scholar
• Bauer S, et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 2014;110(5):1155-62
   PubMed Web of Science ®Google Scholar
• Bhat R, Tummalapalli SR, Rotella DP. Progress in the discovery and development of heat shock protein 90 (hsp90) inhibitors. J Med Chem 2014;57(21):8718-28
   PubMed Web of Science ®Google Scholar
• Parimi S, Tsang RY. Hsp90 inhibitors in oncology: ready for prime time? Curr Oncol 2014;21(5):e663-7
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10(2):86-103
   PubMed Web of Science ®Google Scholar
• Bauer S, et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006;66(18):9153-61
   PubMed Web of Science ®Google Scholar
• Lundgren K, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8(4):921-9
   PubMed Web of Science ®Google Scholar
• Zhang H, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer 2010;126(5):1226-34
   PubMed Web of Science ®Google Scholar
• Saif MW, et al. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin Cancer Res 2014;20(2):445-55
   PubMed Web of Science ®Google Scholar
• Dickson MA, et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 2013;24(1):252-7
   PubMed Web of Science ®Google Scholar
• Chan KC, et al. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer 2013;12(1):128
   PubMedGoogle Scholar
• Smyth T, et al. Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models. Mol Cancer Ther 2014;13(12):2793-804
   PubMed Web of Science ®Google Scholar
• Smyth T, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012;11(8):1799-808
   PubMed Web of Science ®Google Scholar
• Shapiro GI, et al. First-in-Human Phase 1 Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors. Clin Cancer Res 2014;21(1):87-97
   PubMed Web of Science ®Google Scholar
• Hyoung Kim S, et al. The Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes with the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells. J Clin Endocrinol Metab 2014;100(2):e253-61
   PubMed Web of Science ®Google Scholar
• Lee DH, et al. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal 2014;27(2):293-305
   PubMed Web of Science ®Google Scholar
• Sessa C, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013;19(13):3671-80
   PubMed Web of Science ®Google Scholar
• Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res 2014;74(5):1294-300
   PubMed Web of Science ®Google Scholar
• Jhaveri K, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 2014;14(3):154-60
   PubMed Web of Science ®Google Scholar
• Goldman JW, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013;13:152
   PubMed Web of Science ®Google Scholar
• Demetri GD, Heinrich MC, Chmielowski B, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. J Clin Oncol 2011;29:15
   Web of Science ®Google Scholar
• Fahrenholtz CD, et al. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget 2014;5(19):9007-21
   PubMedGoogle Scholar
• Xie Y, et al. Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol Lett 2014;8(5):1993-9
   PubMed Web of Science ®Google Scholar
• Ji QS, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007;6(8):2158-67
   PubMed Web of Science ®Google Scholar
• Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1(6):1153-71
   PubMed Web of Science ®Google Scholar
• Puzanov I, et al. A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors in Patients with Advanced Solid Tumors. Clin Cancer Res 2014;21(4):701-11
   PubMed Web of Science ®Google Scholar
• Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 2012;72(5):1055-8
   PubMed Web of Science ®Google Scholar
• Collins FS. Mining for therapeutic gold. Nat Rev Drug Discov 2011;10(6):397
   PubMed Web of Science ®Google Scholar
• Pessetto ZY, et al. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther 2014;13(10):2276-87
   PubMed Web of Science ®Google Scholar
• Pessetto ZY, et al. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther 2013;12(7):1299-309
   PubMed Web of Science ®Google Scholar
• Boichuk S, et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res 2014;74(4):1200-13
   PubMed Web of Science ®Google Scholar
• Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors. Clin Colorectal Cancer 2006;6(Suppl 1):S7-17
   PubMedGoogle Scholar
• Rutkowski P, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer 2012;12:107
   PubMed Web of Science ®Google Scholar
• Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16
   PubMed Web of Science ®Google Scholar
• Twombly R. Criticism of tumor response criteria raises trial design questions. J Natl Cancer Inst 2006;98(4):232-4
   PubMed Web of Science ®Google Scholar
• Benjamin RS, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011;68(1):69-77
   PubMed Web of Science ®Google Scholar
• Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354(5):496-507
   PubMed Web of Science ®Google Scholar
• Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13(Suppl 2):4-7
   PubMed Web of Science ®Google Scholar
• Van den Abbeele AD, et al. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012;53(4):567-74
   PubMed Web of Science ®Google Scholar
• Wahl RL, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-50S
   PubMed Web of Science ®Google Scholar
• Choi H, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183(6):1619-28
   PubMed Web of Science ®Google Scholar